Amylyx Pharmaceuticals, Inc.
AMLX
Ранг среди акций
#4619
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Цена акции
$26.84
Рыночная капитализация
$3.37B
Изменение (1 день)
1.90%
Изменение (1 год)
79.53%
Страна
US
Торговля Amylyx Pharmaceuticals, Inc. (AMLX)
Категория
Healthcare
EPS для Amylyx Pharmaceuticals, Inc. (AMLX)
EPS по состоянию на June 2026 TTM: $-1.41
Согласно последним финансовым отчетам и цене акций Amylyx Pharmaceuticals, Inc., текущий EPS компании (TTM) составляет $-1.41. В конце 2023 EPS компании составлял $0.73, больше, чем показателю 2022 года, равному $-2.98.
История EPS компании Amylyx Pharmaceuticals, Inc. с 2019 по 2026
EPS на конец каждого года
| Год | EPS | Изменить |
|---|---|---|
| 2026 (TTM) | $-1.41 | -68.17% |
| 2024 | $-4.43 | -706.85% |
| 2023 | $0.73 | -124.50% |
| 2022 | $-2.98 | 96.05% |
| 2021 | $-1.52 | 92.41% |
| 2020 | $-0.79 | 203.85% |
| 2019 | $-0.26 | 0.00% |
EPS для аналогичных компаний или конкурентов
| Компания | EPS | Разница в EPS | Страна |
|---|---|---|---|
| $17.32 | -1,328.37% |
US
|
|
| $-7.98 | 465.96% |
US
|
|
| $-5.29 | 275.18% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,067.38% |
NL
|
